Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study Of "Off-the-Shelf" Neoantigen Vaccine Platform

Author: Benzinga Newsdesk | April 15, 2024 07:15am

Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform.
Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI).
Publication underscores the important role of antigen selection and cassette design in the development of neoantigen-directed immunotherapy.

Posted In: GRTS